Glatiramer Acetate [Design Issues]

posted by Dr_Dan  – Germany, 2014-03-03 13:23 (4496 d 01:55 ago) – Posting: # 12551
Views: 5,705

Dear Chirag
I do not understand why you have to conduct a BE study since your formulation is a solution for subcutaneous injection. The only excipient of the RLD is mannitol and if you do not use a different excipient there should be no formulation effect and consequently a BE study is not necessary.
Please explain.
Thanks in advance.
Kind regards
Dr_Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
100 visitors (0 registered, 100 guests [including 13 identified bots]).
Forum time: 16:19 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5